-+ 0.00%
-+ 0.00%
-+ 0.00%

CDT advances AZD5904 into global PCT patent phase

PUBT·05/06/2026 12:32:48
Listen to the news
CDT advances AZD5904 into global PCT patent phase
  • CDT Equity said AZD5904 moved into Patent Cooperation Treaty phase, extending global patent coverage for the myeloperoxidase inhibitor originally licensed from AstraZeneca.
  • Company holds composition of matter patent plus method-of-use patent covering AZD5904 in idiopathic male infertility.
  • Asset has Phase 1 safety data in 181 subjects across five studies, supporting partnering talks for out-licensing and later-stage development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CDT Equity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060830PRIMZONEFULLFEED9714185) on May 06, 2026, and is solely responsible for the information contained therein.